EDX Medical Group plc (TIDM: EDX), a UK-based clinical diagnostics products and services provider, announced on Monday that it has entered into an exclusive distribution agreement with Caris Life Sciences, a US-based precision medicine and AI TechBio company.

The deal grants EDX Medical the rights to distribute Caris' advanced molecular profiling services in the UK and Nordic countries for a minimum of three years.

Caris Life Sciences offers state-of-the-art molecular profiling, utilizing AI-driven analysis of DNA, RNA and proteins to provide personalised cancer treatment options. The company's platform, one of the most comprehensive globally, includes Whole Exome and Whole Transcriptome Sequencing across over 23,000 genes, helping clinicians make informed treatment decisions.

EDX Medical, listed on the Apex Segment of the AQSE Growth Market, will immediately begin offering Caris' solid tumour and liquid biopsy molecular profiling services in the UK, Sweden, Denmark, Norway and Finland. Further regions and products are expected to follow as part of this collaboration.